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Abstract
Background: Gemcitabine is used as a standard drug treatment for non-small cell lung cancer (NSCLC), but
treatment responses vary among patients. Our previous studies demonstrated that POLA2 + 1747 GG/GA single
nucleotide polymorphism (SNP) improves differential survivability and mortality in NSCLC patients. Here, we
determined the association between POLA2 and gemcitabine treatment in human lung cancer cells.
Results: Human PC9, H1299 and H1650 lung cancer cell lines were treated with 0.01-100 μM gemcitabine for 72 h.
Although all 3 cell lines showed decreased cell viability upon gemcitabine treatment, H1299 was found to be the
most sensitive to gemcitabine treatment. Next, sequencing was performed to determine if POLA2 + 1747 SNP
might be involved in gemcitabine sensitivity. Data revealed that all 3 cell lines harbored the wild-type POLA2 +
1747 GG SNP, indicating that the POLA2 + 1747 SNP might not be responsible for gemcitabine sensitivity in the
cell lines studied. Silencing of POLA2 gene in H1299 was then carried out by siRNA transfection, followed by
gemcitabine treatment to determine the effect of POLA2 knockdown on chemosensitivity to gemcitabine. Results
showed that H1299 exhibited increased resistance to gemcitabine after POLA2 knockdown, suggesting that POLA2
does not act alone and may cooperate with other interacting partners to cause gemcitabine resistance.
Conclusions: Collectively, our findings showed that knockdown of POLA2 increases gemcitabine resistance in
human lung cancer cells. We propose that POLA2 may play a role in gemcitabine sensitivity and can be used as a
prognostic biomarker of patient outcome in NSCLC pathogenesis.
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Background
Lung cancer is a leading cause of cancer mortality world-
wide, accounting for approximately 28% of all cancer
deaths annually. The prognosis for lung cancer is poor.
Most lung cancer patients are diagnosed at advanced stage
and only 16% remained surviving 5 years after initial diag-
nosis. Out of all lung cancer cases, about 85–90% of diag-
nosis are non-small cell lung cancer (NSCLC) [1]. NSCLC
consists of three major tumor subtypes: adenocarcinoma,
large-cell carcinoma and squamous-cell carcinoma.
Therapeutic regimens are platinum-based doublets,
whereby the second agent can be microtubule-targeted
agents, cytidine analogues or DNA-damaging agents [2].
Cytotoxic chemotherapy thus remains as the current
standard cure for patients having advanced NSCLC.
Gemcitabine, a cytidine analogue, is well-known to
have a significant therapeutic effect in NSCLC cases [3].
It is a prodrug that becomes activated by intracellular
kinases to form di- and tri-phosphorylated metabolites,
which together catalyze the conversion of ribonucleotides
to deoxyribonucleotides and terminate DNA synthesis [4].
Studies have shown that the responses of NSCLC patients
to gemcitabine treatment vary, which could be due to
genetic polymorphisms and different gene variants
involved in the gemcitabine pathway [5, 6].
The eukaryotic DNA polymerase α, one of the main
polymerases involved in nuclear DNA replication, is a
four-subunit (A, B, C, D) enzyme which possesses DNA
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polymerase and primase activities. Earlier biochemical stud-
ies have reported that subunit A displays catalytic activity,
while subunits C and D exhibit primase activity [7, 8].
Subunit B, also known as DNA polymerase α2 accessory
subunit (POLA2), is a 70-kDa regulatory subunit which
contributes to DNA replication by binding the DNA poly-
merase α-primase complex to the initiation and elong-
ation machinery [9]. POLA2 is widely expressed in a
variety of tissue types. It has recently been shown to par-
ticipate in gene fusion events and may also act as a prog-
nostic biomarker in ovarian cancer and gastrointestinal
stromal tumors [10, 11]. However, the exact role of
POLA2 in human cancer remains unknown and its in-
volvement in NSCLC pathogenesis remains understudied.
We have previously demonstrated that POLA2 + 1747
GG/GA improves differential survivability and mortality
in NSCLC patients, and proposed that this novel single
nucleotide polymorphism (SNP) may be used as a
prognostic biomarker of patient outcome in NSCLC
pathogenesis [12]. In the current study, we sought to de-
termine the association between POLA2 and gemcita-
bine treatment, and further characterized the role of
POLA2 in human lung cancer cells.
Results
Genomic landscape of POLA2
To understand POLA2 genomic sequence, we first exam-
ined the sequence of POLA2 using the human Dec. 2013
(GRCh38/hg38) assembly on the UCSC Genome Browser
(https://genome.ucsc.edu/). POLA2 is located on chromo-
some 11q13.1 and contains 21 exons. Assessment of the
DNA sequence using data retrieved from the
Encyclopedia of DNA Elements (ENCODE) indicated the
presence of several integrated transcriptional regulatory
elements. Comparative genomics analysis using multiple
alignments of vertebrate species revealed conservation of
the POLA2 gene. We further explored the presence of
SNP sites within the POLA2 genomic region. Figure 1a
shows the location of each SNP, as reported by the Single
Nucleotide Polymorphism database (dbSNP) build 146.
Only SNPs that have a minor allele frequency of at least
1% and are mapped to a single location in the reference
genome assembly are included.
Association of POLA2 with other genes
Recent studies reported that POLA2 may participate in
gene fusion events that can contribute to prognosis in
ovarian cancer and gastrointestinal stromal tumors.
Using data compiled from the National Center for
Biotechnology Information (NCBI) and Gene Ontology
(GO) framework databases, we uncovered 44 unique
interactants for POLA2 (Table 1). These interactants
were inferred from physical interactions, sequence or
structural similarities, as well as direct experimental
assays. Pathway analysis showed that POLA2 predomin-
antly plays a major role in DNA replication, which in-
volves a complex network of other interacting enzymes
and proteins (Fig. 1b). Figure 1c further depicts the
visualization of POLA2 and its interactants in a network,
which was generated based on published and known
physical or genetic interactions, chemical associations
and post-translational modifications.
Effect of gemcitabine on human lung cancer cell lines
To examine the effect of gemcitabine on human lung
cancer cell lines, we treated PC9, H1299 and H1650 cell
lines with 0.01–100 μM gemcitabine for 72 h. As shown
in Fig. 2, cell viability decreased with increasing concen-
trations of gemcitabine treatment. Although all 3 cell
lines showed similar trends of decreasing cell viability
upon gemcitabine treatment, H1299 was found to be the
most sensitive to gemcitabine, having the lowest IC50
among the 3 cell lines studied.
Detection of SNPs in human lung cancer cell lines
The POLA+ 1747 GG/GA SNP and SLC28A2 + 65 CC
SNP are two of the 21 SNPs of the 9 genes involved in
gemcitabine transport, metabolism and activity. From our
in silico prediction analysis reported earlier [12], these two
SNPs gave the best survival outcome and thus of interest
for further studies in vitro. Here, sequencing of PC9,
H1299 and H1650 cell lines revealed that all of these cell
lines harboured the wild-type POLA2 + 1747 SNP (Fig. 3a),
indicating that the POLA2 + 1747 SNP might not be re-
sponsible for gemcitabine sensitivity in the cell lines stud-
ied. Next, to investigate if SLC28A2 + 65 SNP might
be involved in gemcitabine sensitivity, we sequenced
PC9, H1299 and H1650 cell lines for the SLC28A2 +
65 SNP. As shown in Fig. 3b, only H1650 cell line har-
boured the mutation SLC28A2 + 65 CC > CT SNP,
whereas both PC9 and H1299 cell lines contained the
wild-type SLC28A2 + 65 CC SNP. We therefore selected
H1299 and H1650 cell lines for subsequent experiments.
Knockdown of POLA2 gene increased resistance to
gemcitabine treatment
Both H1299 and H1650 cell lines were transfected for
48–72 h with the respective small interfering RNAs
(siRNAs) to silence POLA2 and SLC28A2 genes. How-
ever, H1650 cell line could not be successfully trans-
fected (data not shown), hence only the H1299 cell line
was used for further studies. Western blot analysis
showed that POLA2 protein expression was significantly
attenuated after 72 h of transfection (Fig. 4a). A chemo-
sensitivity assay was then conducted to determine the
effect of POLA2 knockdown on the drug sensitivity of
H1299 cell line to gemcitabine. As shown in Fig. 4b,
H1299 cell line became more resistant to gemcitabine
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Fig. 1 (See legend on next page.)
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upon knockdown of the POLA2 gene. This implied that
other factors and mechanisms might play a role in
contributing to gemcitabine resistance and more work
needs to be done to explore this avenue.
Discussion
Previously, we have demonstrated that the POLA2 + 1747
GG/GA SNP is associated with improved survivability and
mortality in NSCLC patients [12]. In this current study,
we reported that the response to gemcitabine treatment is
related to POLA2 and confirmed that the knockdown of
POLA2 gene increased the resistance to gemcitabine
treatment in human lung cancer cells.
NSCLC is one of the most chemoresistant cancer types.
Clinical treatment using traditional chemotherapy agents
have reached a plateau in NSCLC patients due to resistance
to chemotherapy drugs. Molecular targeted therapy through
interruption of the epithelial growth factor receptor was one
of the earlier treatment strategies used [13]. However, this
strategy failed to achieve remarkable results during clinical
trials [14]. Many factors, including genetic heterogeneity, re-
dundant tumor growth as well as survival signaling path-
ways, likely contributed to the resistance of NSCLC patients
to molecular therapies [15]. As such, genetic studies and the
understanding of signaling mechanisms may help to identify
appropriate treatment strategies for NSCLC patients.
The DNA polymerase α subunit B, which is involved in
the initiation of chromosomal DNA replication, is encoded
by the POLA2 gene. We have previously reported that dif-
ferent variants of the POLA2 gene may improve the prog-
nosis of NSCLC patients [12]. We have demonstrated that
the POLA2 + 1747 GG/GA SNP encodes for a mutant
DNA polymerase α subunit B that is predominantly local-
ized in the cytoplasm. This leads to an inhibition in nuclear
DNA polymerase α activity, thereby conferring a protective
effect on NSCLC patients due to termination of tumor
DNA replication. This inhibition of tumor cell proliferation
ultimately results in tumor cell death.
Gemcitabine is a potent DNA synthesis inhibitor, which
is a deoxycytidine analogue with anti-tumor activity
against various solid tumours such as NSCLC, pancreatic
cancer, breast cancer and ovarian cancer [16]. Gemcita-
bine enters the cell through transport by members of the
nucleoside transporter family SLC28 and SLC29 [17, 18].
It is then activated by the deoxycytidine kinase to its
monophosphate form in a rate-limiting step. The mono-
phosphate form is then further phosphorylated into gem-
citabine triphosphate, which is then incorporated into the
DNA by DNA polymerase α. Through a process of
masked chain termination, DNA synthesis and repair are
prematurely halted [19, 20]. As gemcitabine is involved in
the inhibition of DNA synthesis, it is a suitable drug can-
didate for studying the role of POLA2.
One important aspect of genetic studies is the interac-
tions between SNPs. In a study of SNP-SNP interactions,
a small number of SNPs is genotyped and then tested if
any interactions are present. Such SNP-SNP interaction
studies may help to identify genomic hotspots in human
diseases. The possibility of using statistical modeling by
many types of regression techniques with straightfor-
ward implementation of interaction analysis is also an
additional advantage of SNP-SNP interaction studies.
We have applied biostatistics to calculate the probability
between different SNP pairs and their overall association
to the survival of lung cancer patients [12]. From in
silico prediction using statistics, we found that POLA2 +
1747 GG/GA SNP together with SLC28A2 + 65 CC SNP
were associated with increased median survival. Here, in
this study, we validated these statistical findings through
wet-lab experiments. We hypothesised that having the
POLA + 1747 GG/GA SNP would cause a tumor to be
more sensitive to gemcitabine treatment. By performing
drug sensitivity tests and sequencing the DNA of human
lung cancer cells for the SNP sites of interest, we were
able to monitor whether the presence of POLA + 1747
GG/GA SNP could affect the response to gemcitabine
treatment. Our results showed that all cell lines contained
the wild-type POLA2 gene. We then proceeded to silence
the POLA2 gene by siRNA transfection and found
that instead of causing tumor cell death due to
termination of DNA replication, the cell lines became
more resistant to gemcitabine treatment. This is the
first report to suggest that the POLA2 gene does not
act alone but may cooperate with other genes to
cause drug resistance to gemcitabine. Indeed, we
showed through in silico prediction that several
(See figure on previous page.)
Fig. 1 Genomics analysis of POLA2. a Genomic landscape of POLA2 based on the human Dec. 2013 (GRCh38/hg38) assembly. Location of POLA2
is indicated by a red vertical line on chromosome 11. Coding exons are represented by blocks linked by a horizontal line. CpG islands are shown
as green blocks. Data associated with integrated transcriptional regulatory elements were retrieved from ENCODE. Comparative genomics analysis
using multiple alignments of vertebrate species revealed conservation of the POLA2 gene. Each SNP is shown separately and labeled with the
respective SNP ID reported by dbSNP build 146. Only SNPs that have a minor allele frequency of at least 1% and are mapped to a single location
in the reference genome assembly are shown in the figure. b Eukaryotic DNA replication complex showing the role of POLA2 (boxed in red) in
DNA replication, which involves a complex network of interacting enzymes and proteins. Three DNA polymerases (α, δ and ε) have been identified in
eukaryotes. DNA polymerase α, including POLA2, forms a complex with DNA primase during the process. Source: Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway database. c Network visualization of POLA2 and its interactants. Physical and genetic interactions, including chemical associations
and post-translational modifications, were curated from published datasets and annotated interaction data from NCBI to construct this network
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interacting partners of POLA2 exist. Our findings are
concomitant with those recently reported by Kang et
al. [10], who showed that POLA2 participates in gene
fusion events and may act as a prognostic biomarker in
gastrointestinal stromal tumors.
Earlier studies have reported other genes that caused
resistance to gemcitabine treatment. Davidson et al. [21]
proposed that increased expression of the ribonucleotide
reductase catalytic subunit M1 (RRM1) gene results in
increased resistance to gemcitabine, while Oguri et al.
[22] reported that decreased expression of the multidrug
resistance protein 5 (MRP5) gene leads to an increase in
gemcitabine sensitivity. In addition, studies by Rha et al.
[23] showed that patients with the RRM1 haplotypes
2455 A > G and 2464 G > A tend to be genetically more
resistant to gemcitabine. Collectively, these studies
showed that resistance to gemcitabine are multifactorial,
which involves decreased intracellular accumulation and
alteration of metabolism [24]. Similar factors include
increased gemcitabine degradation enzymes, decreased
gemcitabine regulation enzymes and decreased activity
of nucleoside transporters (SLC28A1 and SLC29A1)
[20, 25, 26]. Other factors such as activation of DNA
repair pathways, negative regulation of apoptosis, al-
terations in cell cycle and cell proliferation pathways, and
transition to a more epithelial-to-mesenchymal transition
(EMT)-like phenotype can also lead to an increased resist-
ance to gemcitabine treatment.
Our findings showed that POLA2 may be a novel gene
that causes resistance to gemcitabine. Similar to the
RRM1 gene, POLA2 is involved in DNA synthesis and
hence, a decrease in its expression might cause the up-
regulation of genes that play a role in DNA synthesis
and repair. These genes and their polymorphisms should
be studied to determine whether there are any SNP-SNP
interactions present among them, as well as with the
POLA2 gene, that could have led to gemcitabine
resistance. Van de Wiel et al. [27] reported chromosomal
aberrations as detected by microarray analysis. Genomewide
gene expression and SNP microarray analyses may
further reveal information on signaling mechanisms
and pathways leading to acquired gemcitabine resist-
ance. We are currently exploring this area to study
which genes are deregulated, leading to drug
Fig. 2 Effect of gemcitabine on human lung cancer cell lines. Human lung cancer cell lines, namely PC9, H1299 and H1650, were treated with 0.01–100 μM
gemcitabine for up to 72 h. Untreated cells (0 μM gemcitabine) were used as the Control. All experiments were conducted in triplicates and repeated at
least 3 times. Data are shown as the mean± SD. Dotted line indicates 50% cell viability
Fig. 3 Detection of SNPs in human lung cancer cell lines. Sequencing
plots of H1650, PC9 and H1299 cell lines for (a) POLA2+ 1747 SNP and (b)
SLC28A+ 65 SNP. All 3 cell lines harboured the wild-type POLA2+ 1747
GG SNP. Only H1650 harboured the mutation SLC28A+ 65 CC>CT SNP,
while both PC9 and H1299 contained the wild-type SLC28A+ 65 CC SNP
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resistance. Studying the gene expression and polymor-
phisms of nucleoside transporters and genes involved
in DNA synthesis and repair can also help to predict
chemosensitivity.
Conclusions
Taken together, our findings suggested that POLA2 may
play a role in gemcitabine resistance. This has important
implications as patients with certain variants of the
POLA2 gene may be resistant to gemcitabine and may
not survive well on gemcitabine treatment. We propose
that POLA2 may be used as a prognostic biomarker of
patient outcome in NSCLC pathogenesis. More work
needs to be done to characterize the correlation between
POLA2 and gemcitabine resistance. Functions of the
POLA2 + 1747 GG/GA SNP should also be further stud-
ied to determine its role in drug resistance and sensitiv-
ity. Our earlier report suggested that the presence of
SLC28A2 + 65 CC/CT SNP may increase the sensitivity
to gemcitabine and thus giving NSCLC patients a better
prognosis [12]. However, as shown in Fig. 1 in our
current study, SLC28A2 + 65 CC SNP has not been
proven to be an interactant of POLA2. Therefore, more
studies are needed to investigate whether SLC28A2 + 65
CC/CT SNP is associated with a better response to gem-
citabine treatment and whether this SLC28A2 + 65 CC/
CT SNP indeed interacts with the POLA2 + 1747 GG/
GA SNP. A larger panel of cell lines carrying either or
both SNPs needs to be screened to obtain a more com-
prehensive overview and we are currently working on
this aspect.
Methods
Genomics analysis of POLA2
The genome sequence of POLA2 was examined using
the human Dec. 2013 (GRCh38/hg38) assembly and
Encyclopedia of DNA Elements (ENCODE) on the
UCSC Genome Browser (https://genome.ucsc.edu/).
Human POLA2 sequence was aligned with genome as-
semblies of other vertebrates and compared using Multiz
Alignments Configuration. SNP sites within the POLA2
genomic region were investigated following the Single
Fig. 4 Effects of POLA2 gene silencing. a Protein expression after knockdown of POLA2 by siRNA. Comparison of POLA2 protein expression in H1299
cell line by Western blotting after 48 and 72 h of siRNA transfection. Internal control for equal loading: glyceraldeyde phosphate dehydrogenase
(GAPDH). b Chemosensitivity assay by comparing IC50 values before and after knockdown of POLA2. Results indicated that the H1299 cell line became
more resistant to gemcitabine treatment after siRNA knockdown of POLA2 (Knockdown), as compared to the non-transfected H1299 cell line having
wild-type POLA2 (Control). Experiments were conducted in triplicates and repeated at least 3 times. Data are shown as the mean ± SD (*p <0.05)
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Nucleotide Polymorphism database (dbSNP; build 146).
Only SNPs having a minor allele frequency of at least
1% and mapped to a single location in the human refer-
ence genome assembly were flagged and included in
subsequent analyses.
Study of SNP-SNP interactions
SNP-SNP interactions of 21 non-synonymous SNPs in 9
genes involved in gemcitabine transport, metabolism
and activity were deduced in silico as reported previ-
ously [12]. Briefly, Fisher’s exact probability test was
used to show that POLA + 1747 GG/GA SNP (rs487989)
was the most statistically significant SNP to be associ-
ated with mortality. Chi-squared test was employed to
assess the association between POLA + 1747 GG/GA
SNP and SLC28A2 + 65 CC SNP, which confirmed that this
SNP pair gave the best survival outcome [12]. All statistical
tests were two-sided and performed using SPSS software
version 14.0 (SPSS Inc., Chicago, IL). Differences were
considered statistically significant when the p-value was less
than 0.05.
Association of POLA2 and other genes
Gene interactions in association with POLA2 were
uncovered using data compiled from the National
Center for Biotechnology Information (NCBI) and Gene
Ontology (GO) framework databases. Interactants were
inferred from physical interactions, sequence or struc-
tural similarities, as well as direct experimental assays.
The Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database was used to further mine for major
pathways involving POLA2. Only experimentally vali-
dated interactants were chosen to generate a network of
interactions using the Biological General Repository for
Interaction Datasets (BioGRID), in which POLA2 plays a
central role.
Cell culture
Human lung cancer H1650 (NCI-H1650) and H1299
(NCI-H1299) cell lines were purchased from American
Type Culture Collection (ATCC; Rockville, MD). Human
lung adenocarcinoma PC-9 cell line was purchased from
RIKEN BioResource Center (Ibaraki, Japan). All cell lines
were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium (Gibco; Thermo Fisher Scientific,
Waltham, MA) containing 10% fetal bovine serum
(HyClone; GE Healthcare Life Sciences, Marlborough,
MA) as recommended by the respective suppliers.
Drug treatment
Cells were seeded into 96-well plates (Nunc; Thermo
Fisher Scientific) at a density of 2 x 104 cells per well in
100 μl culture medium and incubated at 37 °C overnight.
Cells were treated with various concentrations of
gemcitabine (Sigma-Aldrich, St. Louis, MI) on the fol-
lowing day to determine the IC50 values. Final con-
centrations of gemcitabine treatment were 0.01, 0.1,
1, 10 and 100 μM. Cell viability was determined using
the CellTiter 96 AQueous One Solution Cell Prolifer-
ation Assay (MTS; Promega, Madison, WI) following
manufacturer’s instructions.
Sequencing
Cell lines were sequenced to confirm the presence of the
POLA2 + 1747 and SLC28A2 + 65 SNPs (Axil Scientific,
Singapore). Sequencing results were then correlated with
the IC50 values to assess the SNP association previously
reported [12].
Silencing of POLA2 + 1747 by siRNA transfection
Silencing of the POLA2 gene was done by siRNA
transfection using DharmaFECT transfection reagents
(Dharmacon, Lafayette, CO) following manufacturer’s
instructions. The H1299 cell line was used, as this cell
line had been tested and validated by the manufacturer.
Transfection durations were 24, 48 and 72 h. Western
blotting was then performed to check for protein expres-
sion of the silenced gene, as described previously [12].
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